LRLars Rydén

Lars Rydén

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lars Rydén has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TEACHING EXPERIENCE OF SUSTAINABLE DEVELOPMENT COURSE IN POST-SOVIET COUNTRIES

    by Lars Rydén, Larysa Bezzubko, Rustam Eshniyazov, Bjorn Frostell, Bo Libert, Borys Bezzubko

    The purpose of this article is to develop proposals for improving the organization of training by foreign teachers in national higher educational institutions (based on the analysis of the experience of teaching the course “Sustainable Development and Sustainablity Science” at the Karakalpak State University, Nukus, Uzbekistan). Using the example of teaching a joint course by Uzbek and Swedish specialists at a higher educational institution in Uzbekistan, the authors described the features, the most important aspects and advantages of this training. The use of the method of comparative analysis, sociological research methods allowed us to identify problems in the organization and conduct of training. As a result of the survey, positive results for students and national teachers were systematized. The authors have developed recommendations for improving the organization of education at universities in post-Soviet republics with the involvement of foreign professors. It was concluded that in the context of globalization, it is necessary to develop cooperation between universities, to carry out a constant exchange of experience.

  • Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial

    by Kelley R.H. Branch, Gilles R. Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Petr Jansky, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, et al.

    Aims: People with diabetes are at high risk for cardiovascular events including heart failure (HF). We examined the effect of the glucagon‐like peptide 1 agonist dulaglutide on incident HF events and other cardiovascular outcomes in those with or without prior HF in the randomized placebo‐controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Methods and results: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non‐fatal myocardial infarction, non‐fatal stroke, or death from cardiovascular causes (including unknown causes). In this post‐hoc analysis, a HF event was defined as an adjudication‐confirmed hospitalization or urgent evaluation for HF. Of the 9901 participants studied over a median follow‐up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a HF event (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.77–1.12; p = 0.456). In the 853 (8.6%) participants with HF at baseline, there was no change in either MACE or HF events with dulaglutide as compared to participants without HF ( p = 0.44 and 0.19 for interaction, respectively). Combined cardiovascular death and HF events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI 0.78–1.00; p = 0.050) but unchanged in patients with and without HF at baseline ( p = 0.31). Conclusions: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow‐up.


  • Open Access

    SURF – SUrvey of Risk Factor management: first report of an international audit

    by Mt Cooney, Z Reiner, W Sheu, L Ryden, J de Sutter, D De Bacquer, G DeBacker, A Mithal, N Chung, Yt Lim, et al.

    Background Despite the fact that subjects with established coronary heart disease (CHD) are at high risk of further events and deserve meticulous secondary prevention, current audits such as EUROASPIRE show poor control of major risk factors. Ongoing monitoring is required. We present a new risk factor audit system, SURF (Survey of Risk Factor management), that can be conducted much more quickly and easily than existing audit systems and has the potential to allow hospitals of all sizes to participate in a unified international audit system that will complement EUROASPIRE. Initial experience indicates that SURF is truly simple to undertake in an international setting, and this is illustrated with the results of a substantive pilot project conducted in Europe and Asia. Methods The data collection system was designed to allow rapid and easy data collection as part of routine clinic work. Consecutive patients (aged 18 and over) with established CHD attending outpatient cardiology clinics were included. Information on demographics, previous coronary medical history, smoking history, history of hypertension, dyslipidaemia or diabetes, physical activity, attendance at cardiac rehabilitation, cardiac medications, lipid and glucose levels (and HbA1c in diabetics) if available within the last year, blood pressure, heart rate, body mass index, and waist circumference were collected using a one-page data collection sheet. Years spent in full time education was added as an additional question during the pilot phase. Results Three European countries − Ireland (n = 251), Belgium (n = 122), and Croatia (n = 124) − and four Asian countries − Singapore (n = 142), Taiwan (n = 334), India (n = 97), and Korea (n = 45) − were included in the pilot study. The results of initial field testing were confirmed in that it proved possible to collect data within 60−90 seconds per subject. There was poor control of several risk factors including high levels of physical inactivity (41−45%), overweight and obesity (59−78%), and ongoing smoking (15%). There were lower levels of individuals attending cardiac rehabilitation in Asia. More Europeans than Asians reached the low-density lipoprotein cholesterol target of Conclusions This phase of SURF has confirmed its ease of use which should allow wide participation and the collection of representative risk factor data in subjects with CHD as well as ongoing data collection to monitor secular trends in risk factor control. Notwithstanding that this is a pilot study, the results suggest that risk factor control, particularly for lifestyle-related measures, is poor in both Europe and Asia.


  • Covalent Chromatography

    by Francisco Batista‐Viera, Lars Rydén, Jan Carlsson


  • Introduction to Protein Purification

    by Bo Ersson, Lars Rydén, Jan‐Christer Janson


  • Open Access

    Ischemic and Nonischemic Tissue Concentrations of Felodipine After Coronary Venous Retroinfusion During Myocardial Ischemia and Reperfusion

    by Yoshiyuki Haga, Yozo Uriuda, Jan-Arne Björkman, Nobuo Hatori, Lars Johansson, Rolf Nordlander, Per-Ove Sjöquist, Lars Rydén

    Summary: Tissue and plasma concentrations of felodipine, a dihydropyridine (DHP) calcium antagonist, retroinfused through the coronary venous system were studied in 27 pigs. The animals underwent 45-min myocardial ischemia followed by 4-h reperfusion. Felodipine (7 nmol/kg body weight) was administered in the coronary vein for 30 min, 5 min before reperfusion. Concentrations of felodipine in the ischemic and nonischemic myocardium and in plasma were determined by gas chromatography. In the ischemic area, felodipine concentration at start of reperfusion was 304 ± 285, 171 ± 160, and 52 ± 47 nmol/kg (mean ± SD) in the subepicardial, midmyocardial, and subendocardial layer, respectively. Corresponding concentrations in the nonischemic area were 15 ± 13, 17 ± 14, and 16 ± 15 nmol/kg (p < 0.05 vs. ischemic area). Subepicardial concentration was highest at start of reperfusion, whereas concentrations in other layers peaked at the end of retroinfusion. The transmural concentration gradient of felodipine in the ischemic area decreased progressively during the reperfusion period. The nonischemic tissue concentration increased slightly during the reperfusion period. The plasma concentration was very low throughout the study (peak = 3.2 ± 1.4 nM at 30 min). Coronary venous retroinfusion of felodipine resulted in profound accumulation of the drug, specifically in ischemic myocardium. The plasma concentration was low and did not affect systemic hemodynamics. Coronary venous retroinfusion is considered an advantageous technique for selective drug delivery.